IP Library Granted Patent US 9,604,978
Granted Patent B2
US 9,604,978 · App. 14/115,506 · Granted Mar 28, 2017

Compounds for inflammation and immune-related uses

Inventors: Shoujun Chen (Bedford, MA); Gary Bohnert (Wilmington, MA); Jun Jiang (Norwood, MA); Zhiqiang Xia (Acton, MA)
Assignee: Synta Pharmaceuticals Corp.
C07D417/14A61K31/165A61K31/44A61K31/497C07D213/82C07D401/12C07D401/14C07D405/14C07D413/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,604,978
App. No.
14/115,506
Granted
Mar 28, 2017
Kind
B2
Abstract

The invention relates to certain compounds or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Claims (165)

1. A compound selected from the group consisting of:

Number

Structure

Compound Name

1.

N-(5-(2-chloro-5-( 1 H-pyrazol-4- yl)phenyl)pyrazin-2-yl)-4- methylnicotinamide

2.

N-(5-(2-ethoxy-5-(1-methyl- 1 H- pyrazol-4-yl)phenyl)pyrazin-2-yl)- 4-methylnicotinamide

3.

N-(5-(2-chloro-5-(2-methylthiazol-4- yl)phenyl)pyrazin-2-yl)-4- methylnicotinamide

6.

5-fluoro-N-(5-(2-methoxy-5-(1-methyl- 1 H-pyrazol-4-yl)phenyl)pyrazin- 2-yl)-4-methylnicotinamide

8.

N-(5-(2-ethyl-5-(1-methyl- 1 H- pyrazol-4-yl)phenyl)pyrazin-2-yl)- 4-methylnicotinamide

14.

N-(5-(2-chloro-5-(5-methylthiazol-2- yl)phenyl)pyrazin-2-yl)-4- methylnicotinamide

16.

N-(5-(2-chloro-5-(pyrimidin-2- yloxy)phenyl)pyrazin-2-yl)-4- methylnicotinamide

19.

N-(5-(2-isopropoxy-5-(1-methyl- 1 H-pyrazol-4-yl)phenyl)pyrazin-2- yl)-4-methylnicotinamide

22.

5-fluoro-4-methyl-N-(5-(5-(1-methyl- 1 H-pyrazol-4-yl)-2- (trifluoromethoxy)phenyl)pyrazin- 2-yl)nicotinamide

24.

N-(5-(2-chloro-5-(3-fluoropyridin- 4-yl)phenyl)pyrazin-2-yl)-4- methylnicotinamide

26.

N-(5-(2-chloro-5-(2-methyl-2H- tetrazol-5-yl)phenyl)pyrazin-2-yl)- 5-fluoro-4-methylnicotinamide

27.

N-(5-(2-ethyl-5-(2-methyl-2H- tetrazol-5-yl)phenyl)pyrazin-2-yl)- 5-fluoro-4-methylnicotinamide

34.

N-(5-(2-chloro-5-((6- (trifluoromethyl)pyridin-2- yl)oxy)phenyl)pyrazin-2-yl)-4- methylnicotinamide

36.

N-(5-(5-((3-fluoropyridin-2- yl)oxy)-2-methylphenyl)pyrazin- 2-yl)-4-methylnicotinamide

38.

N-(5-(5-((3-fluoropyridin-2-yl)oxy)-2- (trifluoromethoxy)phenyl)pyrazin- 2-yl)-4-methylnicotinamide

39.

N-(5-(2-cyano-5-(oxetan-3- yloxy)phenyl)pyrazin-2-yl)-4- methylnicotinamide

44.

4-methyl-N-(5-(2-methyl-5-(pyridin- 3-ylethynyl)phenyl)pyrazin-2- yl)nicotinamide

45.

4-methyl-N-(5-(2-methyl-5-(2-methyl- 2H-tetrazol-5-yl)phenyl)pyrazin- 2-yl)nicotinamide

49.

N-(5-(2-chloro-5-(pyridin-2- yloxy)phenyl)pyrazin-2-yl)-4- methylnicotinamide

50.

4-methyl-N-(5-(6- methylbenzo[d][1,3]dioxol-5- yl)pyrazin-2-yl)nicotinamide

51.

4-methyl-N-(5-(5-(pyridin-2-yloxy)-2- (trifluoromethoxy)phenyl)pyrazin- 2-yl)nicotinamide

52.

4-methyl-N-(5-(2-methyl-5-(1-methyl- 1 H-pyrazol-4-yl)phenyl)pyrazin-2- yl)nicotinamide

53.

N-(5-(2-chloro-5-(1-methyl- 1 H- pyrazol-4-yl)phenyl)pyrazin-2-yl)- 4-methylnicotinamide

54.

N-(5-(2-chloro-5-(pyridin-2- yloxy)phenyl)pyrazin-2-yl)-5- fluoro-4-methylnicotinamide

56.

N-(5-(2-ethyl-5-(2-methyl-2H- tetrazol-5-yl)phenyl)pyrazin-2-yl)- 4-methylnicotinamide

57.

N-(5-(2-chloro-5-(2-methyl-2H- tetrazol-5-yl)phenyl)pyrazin-2-yl)- 4-methylnicotinamide

61.

N-(5-(2,5-dimethoxy- 1 H- benzo[d]imidazol-1-yl)pyrazin-2- yl)-4-methylnicotinamide

62.

N-(5-(2-chloro-5- cyclopropoxyphenyl)pyrazin-2- yl)-4-methylnicotinamide

65.

N-(5-(5-methoxy-2-(trifluoromethyl)- 1 H-benzo[d]imidazol-1-yl)pyrazin-2- yl)-4-methylnicotinamide

66.

N-(5-(5-cyclopropoxy-2- methylphenyl)pyrazin-2-yl)-4- methylnicotinamide

68.

4-methyl-3-(5-(4- methylnicotinamido)pyrazin-2- yl)phenyl dimethylsulfamate

69.

4-methyl-3-(5-(4- methylnicotinamido)pyrazin-2- yl)phenyl methanesulfonate

79.

N-(5-(5-cyclopropoxy-2- methylphenyl)pyrazin-2-yl)-5- fluoro-4-methylnicotinamide

80.

N-(5-(2-chloro-5-(1,5-dimethyl- 1 H-pyrazol-4-yl)phenyl)pyrazin-2- yl)-4-methylnicotinamide

81.

5-bromo-N-(5-(2-chloro-5- cyclopropoxyphenyl)pyrazin-2- yl)-4-methylnicotinamide

85.

N-(5-(2-chloro-5-((3-fluoropyridin-2- yl)oxy)phenyl)pyrazin-2-yl)-4- methylnicotinamide

86.

N-(5-(2-cyclopropoxy-5-(1-methyl- 1 H-pyrazol-4-yl)phenyl)pyrazin-2-yl)- 4-methylnicotinamide

87.

N-(5-(2-chloro-5- cyclopropoxyphenyl)pyrazin-2-yl)-4- methylnicotinamide hydrochloride

93.

4-chloro-3-(5-(4- methylnicotinamido)pyrazin-2- yl)phenyl methanesulfonate

101.

4-methyl-N-(5-(2-methyl-5-(1-methyl- 1 H-pyrazol-3-yl)phenyl)pyrazin-2- yl)nicotinamide

110.

N-(5-(2-methoxy-5-(1-methyl- 1 H- pyrazol-4-yl)phenyl)pyrazin-2-yl)- 4-methylnicotinamide

114.

5-chloro-N-(5-(2-chloro-5-(1-methyl- 1 H-pyrazol-4-yl)phenyl)pyrazin-2- yl)-4-methylnicotinamide

121.

5-bromo-N-(5-(2-chloro-5-(1-methyl- 1 H-pyrazol-4-yl)phenyl)pyrazin-2- yl)-4-methylnicotinamide

123.

N-(5-(2-chloro-5-(1-methyl- 1 H- pyrazol-4-yl)phenyl)pyrazin-2-yl)- 5-fluoro-4-methylnicotinamide

124.

4-methyl-N-(5-(2-methyl-5-(2- methylthiazol-4-yl)phenyl)pyrazin-2- yl)nicotinamide

129.

N-(5-(2-chloro-5-(1-methyl- 1 H- pyrazol-4-yl)phenyl)pyrazin-2-yl)- 4,5-dimethylnicotinamide

131.

N-(5-(2-chloro-5-(1-methyl- 1 H- pyrazol-4-yl)phenyl)pyrazin-2-yl)- 5-ethyl-4-methylnicotinamide

132.

N-(5-(2-chloro-5-(1-methyl- 1 H- pyrazol-4-yl)phenyl)pyrazin-2-yl)- 5-cyano-4-methylnicotinamide

137.

N-(5-(2-ethyl-5-((5-methylisoxazol-3- yl)oxy)phenyl)pyrazin-2-yl)-4- methylnicotinamide

142.

N-(5-(2-chloro-5-(1-methyl- 1 H- pyrazol-4-yl)phenyl)pyrazin-2-yl)- 4-methylnicotinamide hydrochloride

143.

5-fluoro-N-(5-(5-((3-fluoropyridin-2- yl)oxy)-2-methylphenyl)pyrazin-2-yl)- 4-methylnicotinamide

144.

N-(5-(2-chloro-5- isopropoxyphenyl)pyrazin-2-yl)-4- methylnicotinamide

196

N-(5-(2-chloro-5- cyclopropoxyphenyl)pyrazin-2-yl)-4- methylnicotinamide hydrochloride

198

N-(5-(2-chloro-5-(oxetan-3- yloxy)phenyl)pyrazin-2-yl)-5- fIuoro-4-methylnicotinamide

200

N-(5-(2-chloro-5- cyclobutoxyphenyl)pyrazin-2-yl)- 5-fluoro-4-methylnicotinamide

201

5-chloro-N-(5-(5-cyclopropoxy-2- methylphenyl)pyrazin-2-yl)-4- methylnicotinamide

202

N-(5-(2-chloro-5- (cyclohexyloxy)phenyl)pyrazin-2- yl)-5-fluoro-4-methylnicotinamide

203

N-(5-(2-cyano-5- cyclopropoxyphenyl)pyrazin-2- yl)-5-fluoro-4-methylnicotinamide

204

N-(5-(2-chloro-5- (cyclopropylmethoxy)phenyl)pyrazin- 2-yl)-4-methylnicotinamide

205

N-(5-(2-cyano-5- cyclopropoxyphenyl)pyrazin-2- yl)-4-methylnicotinamide

206

N-(5-(2-chloro-5- (cyclopentyloxy)phenyl)pyrazin-2- yl)-4-methylnicotinamide

207

N-(5-(2-chloro-5- cyclopropoxyphenyl)pyrazin-2- yl)-5-fluoro-4-methylnicotinamide

208

N-(5-(5-cyclopropoxy-2- ethylphenyl)pyrazin-2-yl)-5- fluoro-4-methylnicotinamide

209

N-(5-(5-cyclopropoxy-2- ethylphenyl)pyrazin-2-yl)-4- methylnicotinamide

212

N-(5-(2-chloro-5- isopropoxyphenyl)pyrazin-2-yl)-4- methylnicotinamide

224

5-fluoro-4-methyl-N-(5-(2-methyl-5-((5- methylthiazol-2-yl)oxy)phenyl)pyrazin- 2-yl)nicotinamide

227

4-methyl-N-(5-(2-methyl-5-((3-methyl- 1,2,4-thiadiazol-5-yl)oxy)phenyl)pyrazin- 2-yl)nicotinamide

228

5-fluoro-4-methyl-N-(5-(2-methyl-5- ((3-methyl-1,2,4-thiadiazol-5- yl)oxy)phenyl)pyrazin-2-yl)nicotinamide

230

N-(5-(2-chloro-5- (trifluoromethoxy)phenyl)pyrazin- 2-yl)-4-methylnicotinamide

231

N-(5-(2-ethyl-5- (trifluoromethoxy)phenyl)pyrazin- 2-yl)-4-methylnicotinamide

240

5-fluoro-4-methyl-N-(5-(2-methyl- 5-(pyrimidin-2-yloxy)phenyl)pyrazin- 2-yl)nicotinamide

And

242

N-(5-(2-chloro-5-(pyrimidin-2- yloxy)phenyl)pyrazin-2-yl)-5- fluoro-4-methylnicotinamide

or a pharmaceutically acceptable salt, or solvate thereof.

2. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable excipient.

3. The compound of claim 1 of the formula:

or a pharmaceutically acceptable salt, or solvate thereof.

4. The compound of claim 1 of the formula:

or a pharmaceutically acceptable salt, or solvate thereof.

5. The compound of claim 1 of the formula:

or a pharmaceutically acceptable salt, or solvate thereof.

6. The compound of claim 1 of the formula:

or a pharmaceutically acceptable salt, or solvate thereof.

7. The compound of claim 1 of the formula:

or a pharmaceutically acceptable salt, or solvate thereof.

8. The compound of claim 1 of the formula:

or a pharmaceutically acceptable salt, or solvate thereof.

9. The compound of claim 1 of the formula:

or a pharmaceutically acceptable salt, or solvate thereof.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2018
From: MADRIGAL PHARMACEUTICALS, INC.
To: PRCL RESEARCH INC.
Reel/Frame 044796/0568 →
CHANGE OF NAME Recorded Feb 1, 2018
From: SYNTA PHARMACEUTICALS CORP.
To: MADRIGAL PHARMACEUTICALS, INC.
Reel/Frame 045216/0415 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2015
From: CHEN, SHOUJUN; BOHNERT, GARY; JIANG, JUN; XIA, ZHIQIANG
To: SYNTA PHARMACEUTICALS CORP.
Reel/Frame 035194/0256 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2015
From: BOHNERT, GARY; CHEN, SHOUJUN; JIANG, JUN; XIA, ZHIQIANG
To: SYNTA PHARMACEUTICALS CORP.
Reel/Frame 035194/0633 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2015
From: BOHNERT, GARY; CHEN, SHOUJUN
To: SYNTA PHARMACEUTICALS CORP.
Reel/Frame 035223/0504 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2015
From: CHEN, SHOUJUN; BOHNERT, GARY; JIANG, JUN; XIA, ZHIQIANG
To: SYNTA PHARMACEUTICALS CORP.
Reel/Frame 035223/0518 →
Continuity (5)
Provisional Application 61481797 · May 3, 2011
Provisional Application 61506403 · Jul 11, 2011
Provisional Application 61552683 · Oct 28, 2011
Provisional Application 61566870 · Dec 5, 2011
Related Publication 20140171446A1 · Jun 19, 2014